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insurance reimbursement from total cost was 8.8%, the proportion
of TB control project reimbursement from total costwas 33.8%, out-
of-pocket payment was account for 44.8% of total cost and 5.8% of
disposablehousehold income in2012. But therewas still about 6.5%
of PTB reached catastrophic health expenditure (>40%of disposable
income).
Conclusion: The direct medical costs of whole course of treat-
ment for PTB patients in Shanghai were relatively high, especially
the costs of hepatoprotectants, liver function laboratory test and
CT examination. Current TB control project reduced the economic
burden of PTB patients in a certain extent, but the item and pro-
portion of reimbursement, and the procedure of the cost reduction
still need to be optimized.
http://dx.doi.org/10.1016/j.ijid.2016.02.844
Type: Poster Presentation
Final Abstract Number: 43.107
Session: Poster Session III
Date: Saturday, March 5, 2016
Time: 12:45-14:15
Room: Hall 3 (Posters & Exhibition)
Conﬁrmation of silent mutations in the rpoB
gene locus of M. tuberculosis isolates using
pyrosequencing and phenotypic DST
N.N. Hirani
Grant Government Medical College and Sir J. J. Group
of Hospitals, Mumbai, Maharashtra, India
Background: More than 95% cases of rifampicin resistance in
M.tuberculosis strains can be attributed to mutations in 81-bp
hotspot region of rpoB gene locus called Rifampicin Resistance
Determining Region. These mutations can be detected by rapid
molecular diagnostic techniques such as Line Probe Assay (LPA),
but detection of silent mutations on LPA may not necessarily con-
fer rifampicin resistance and result in false rifampicin resistance
reporting. These silent mutations can be conﬁrmed by phenotypic
Drug Sensitivity Testing (DST) and/or by DNA sequencing.
Following study was undertaken to conﬁrm silent mutations
using phenotypic DST (Gold standard) and pyrosequencing, a rapid
real timemethod for sequencing small DNA segments by synthesis.
Methods & Materials: Total 300 DNA extracts comprising of
101 silent mutation strains; 101 pan-sensitive, 96 MDR-TB and 02
rifampicinmono-resistant strainswereprocessed forpyrosequenc-
ing following detection by LPA.
Pyrosequencingwas performedwith sequence analysismode of
PyroMark Q96 ID system (Qiagen, Valencia, CA).
All 300 sputumconcentrateswerealsoprocessed forphenotypic
DST, using solid and liquid culture methods.
Results: Pyrosequencing detected mutations in all 101 silent
mutation strains, but 02 strains did not produce amino acid change
(true silent mutations) and were also rifampicin sensitive pheno-
typically. Maximum mutations were seen in 526 codon(35 strains)
followed by 511 codon region(30 strains). Two novel mutations
were reported: substitution in 529 codon CGA”CAA and 517-518
codon deletion.
However, only 51/99 true rifampicin resistant strains on Pyrose-
quencingwere rifampicin resistant byMGIT 960 and 57/99 by solid
DST. This proves that low level rifampicin resistance linked to spe-
ciﬁc rpoB mutations could be missed by phenotypic DST and this
could be attributed to the critical concentration of rifampicin used.
101pan-sensitive, 96MDR-TBand02rifampicinmono-resistant
strains used as controls were conﬁrmed by pyrosequencing and
showed 100% concordance with phenotypic DST.
Conclusion: Pyrosequencing is a conﬁrmatory tool for detection
of rifampicin resistance in silent mutation cases in M. tuberculosis
and reiterates the fact that liquid DST may miss some rifampicin
resistance compared to solid DST conferring mutations further
suggesting that the gold standard for rifampicin resistance be
reconsidered. Treatment outcome with these mutations is not well
known.
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Background: Against the backdrop evidenced in the threat
Tuberculosis poses to developing economies, especially its preva-
lence among people in their productive (15-45) years; this
preliminary study examined the phytochemical constituents and
antimycobacterial effect of four (4) aqueous and ethanolic extracts
from the fruit skin (epicarp) and leaf of Annona muricata Linn.
Methods & Materials: Extracts were prepared with distilled
water and 95% ethanol according to methods previously described.
Phytochemical analysis of the extracts were carried out follow-
ing standard protocols while the antimycobacterial activity was
assayed by employing the Drug susceptibility testing (DST) pro-
cedure in a Biosafety Level 3 facility. Lowenstein Jensen (LJ) media
were prepared with extracts at three concentrations (1, 40 and 250
g/ml) following the project design and subsequently inoculated
with 10-3 and 10-5 suspensions of both control (H37Rv) strain and a
clinical isolate (MTB-584) of Mycobacterium tuberculosis. LJ media
prepared with Rifampicin at 40 g/ml was used as the standard
drug for positive control while plain media with respective inocu-
lum served as negative control. Four Ziehl-Neelsen’s stain slides
were also prepared to conﬁrm the presence of organisms in the
two suspensions employed for the two strains tested. Plain media
inoculated with distilled water were employed as normal control
to check for possible contaminant. The inoculated media and con-
trol slants were placed in an incubator at 37oC and observed every
seven days for a period of 4 – 6 weeks.
